Plain-English translation of NCT06914128 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This is an early-stage research study testing a new medication called in people with a specific type of cancer — solid tumors that have lost a gene called MTAP. Researchers believe this medication works by blocking a protein that helps cancer cells survive, which may kill the cancer while leaving healthy cells alone. The study will test whether the medication is safe, how your body processes it, and whether it helps shrink or stop your cancer.
Most cancers with MTAP-deletion are difficult to treat with current therapies. This trial exists to see if this medication could offer a new treatment option for people with this genetic type of cancer.
You likely qualify if…
You likely don't qualify if…
The study has two main phases: first, small groups will receive gradually increasing doses to find the safest and most effective dose; then, larger groups will receive that dose either alone or combined with other treatments. You will visit the study site regularly for blood tests, heart monitoring, scans, and physical exams to check how you're responding and for any side effects. You can continue taking the medication as long as it's helping your cancer and you're not having severe problems.
AI-generated summary from trial data · Jun 29, 2026 · Not medical advice
United States